Table 4. Clinicopathological variables of patients stratified by preoperative serum cystatin-C.
| Characteristics | Cystatin-C≤1.09 mg/L (n = 216) | Cystatin-C>1.09 mg/L (n = 109) | P-value |
|---|---|---|---|
| Age, (years) | 49.00 (18.00–78.00) | 56.00 (25.00–84.00) | <0.001 a |
| BMI, (kg/m2) | 23.44 (16.02–35.67) | 23.62 (15.41–38.76) | 0.592 a |
| Gender | 0.008 b | ||
| Male | 137 (63.40%) | 85 (78.00%) | |
| Female | 79 (36.60%) | 24 (22.00%) | |
| pT-stage | <0.001 b | ||
| pT1 | 175 (81.00%) | 60 (55.00%) | |
| pT2 | 30 (13.90%) | 23 (21.10%) | |
| pT3 | 8 (3.70%) | 18 (16.50%) | |
| pT4 | 3 (1.40%) | 8 (7.30%) | |
| pN-stage | 0.036 b | ||
| pN0 | 207 (95.80%) | 98 (89.90%) | |
| pN1 | 9 (4.20%) | 11 (10.10%) | |
| pM-stage | 0.020 b | ||
| pM0 | 208 (96.30%) | 98 (89.90%) | |
| pM1 | 8 (3.70%) | 11 (10.10%) | |
| pTNM-stage | <0.001 b | ||
| Ⅰ | 171 (79.20%) | 56 (51.40%) | |
| Ⅱ | 27 (12.50%) | 19 (17.40%) | |
| Ⅲ | 8 (3.70%) | 18 (16.50%) | |
| Ⅳ | 10 (4.60%) | 16 (14.70%) | |
| Fuhrman grade | 0.005 b | ||
| Ⅰ | 36 (16.70%) | 11 (10.10%) | |
| Ⅱ | 103 (47.70%) | 53 (48.60%) | |
| Ⅲ | 16 (7.40%) | 21 (19.30%) | |
| Ⅳ | 3 (1.40%) | 4 (3.70%) | |
| Unknown | 58 (26.90%) | 20 (18.30%) | |
| Pathological types | 0.016 b | ||
| Clear cell carcinoma | 163 (75.50%) | 97 (89.00%) | |
| Papillary carcinoma | 16 (7.40%) | 4 (3.70%) | |
| Others | 37 (17.10%) | 8 (7.30%) | |
| Preoperative ALP (U/L) | 70.90 (16.00–237.30) | 77.90 (27.50–419.00) | 0.002 a |
| Preoperative TP (g/L) | 72.67 (29.65–93.46) | 72.75 (56.82–85.09) | 0.481 a |
| Preoperative CRE (μmol/L) | 70.85 (38.10–123.60) | 84.60 (40.80–221.90) | <0.001 a |
| Preoperative UA (μmol/L) | 347.95 (120.70–589.60) | 378.70 (112.60–616.30) | 0.008 a |
| Preoperative e-GFR (mL/min/1.73 m2) | 83.33 (35.82–144.31) | 65.66 (16.31–131.90) | <0.001 a |
Abbreviation: BMI: body mass index; ALP: alkaline phosphatase; TP: total protein; UA: uric acid; CRE: creatinine; e-GFR: estimated glomerular filtration rate.
a Kraskal-Wallis test
b Chi-square test